#AS­CO19: Am­gen shows off their lat­est BC­MA BiTE up­date with plans to hus­tle ahead as ri­vals jos­tle for po­si­tion

CHICA­GO — Am­gen’s R&D team is quite proud of their pro­gram for AMG 420, a BC­MA-tar­get­ed bis­pe­cif­ic T cell en­gager they plan to hus­tle through piv­otal stud­ies in search of an ac­cel­er­at­ed OK by the FDA. And the whole BiTE plat­form is be­ing de­vel­oped as an av­enue to great­ly ex­pand their pres­ence in the on­col­o­gy mar­ket.

The phar­ma gi­ant was on hand at AS­CO to of­fer the lat­est up­date — a com­mon theme at the meet­ing this year — on ‘420, while shar­ing the lime­light with some of the rest of the BiTEs now work­ing their way up the pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER